Revolutionizing Tumor Infiltrating Lymphocyte Restimulation for Enhanced Anti-Tumor Efficacy

A next-generation approach to restimulating cryopreserved tumor infiltrating lymphocytes, leveraging metabolic reconditioning, personalized neoantigen-based vaccines, and advanced monitoring and prediction tools to unlock unprecedented anti-tumor potency and patient outcomes.

The original patent, 'Restimulation of cryopreserved tumor infiltrating lymphocytes,' demonstrated the potential of adoptive transfer of tumor infiltrating lymphocytes (TILs) for treating bulky, refractory cancers. However, the current approach has limitations, including suboptimal TIL viability, anti-tumor efficacy, and patient-specific variability. The new inventive concept addresses these limitations by introducing a paradigm shift in TIL restimulation, enabling more effective and personalized cancer therapies.

The inventive concept encompasses a system for rejuvenating cryopreserved TILs, comprising a metabolic reconditioning module that adjusts glycolytic and mitochondrial metabolic pathways to optimize T cell viability and anti-tumor efficacy. Additionally, the concept includes a method for generating personalized neoantigen-based vaccines, wherein cryopreserved TILs are restimulated with patient-specific neoantigen libraries to induce robust and durable anti-tumor immune responses. Furthermore, the concept involves a composition of matter comprising cryopreserved TIL products restimulated with small molecule inhibitors of glycolysis and activators of mitochondrial biogenesis, resulting in enhanced anti-tumor potency. The concept also includes a device for real-time monitoring of TIL metabolism during restimulation, featuring a microfluidic chamber and sensor array for detecting changes in glycolytic flux, mitochondrial membrane potential, and ATP production. Finally, the concept incorporates a computer-implemented method for predicting TIL restimulation outcomes, utilizing machine learning algorithms that integrate genomic, transcriptomic, and metabolomic data from cryopreserved TILs to identify optimal restimulation protocols for individual patients.

The new claims introduce a novel, non-obvious approach to TIL restimulation, leveraging metabolic reconditioning, personalized neoantigen-based vaccines, and advanced monitoring and prediction tools. These innovations overcome the limitations of the original patent, enabling more effective, personalized, and adaptive cancer therapies.

Alternative embodiments of the inventive concept could include variations in the metabolic reconditioning module, such as using different small molecule inhibitors or activators, or incorporating additional signaling pathways. Additionally, the personalized neoantigen-based vaccine approach could be adapted for use with other types of immune cells or cancer therapies. The real-time monitoring device could be modified to detect different metabolic parameters or integrated with other analytical tools. The computer-implemented prediction method could be expanded to incorporate additional data sources or machine learning algorithms.

The inventive concept has significant commercial potential in the cancer immunotherapy market, with applications in adoptive T cell therapy, personalized neoantigen-based vaccines, and companion diagnostics. The market for cancer immunotherapies is rapidly growing, with projected values exceeding $100 billion by 2025. The inventive concept's ability to enhance anti-tumor efficacy, improve patient outcomes, and provide personalized treatment options positions it for significant market share and revenue potential.